Company intelligence / Profile preview

Inversago Pharma

Ownership: Private
Development stage: Phase 2

Overview

Lead program INV-202 demonstrated weight loss potential in a Phase 1b trial and is currently in Phase 2 trials for diabetic kidney disease and obesity. The company is developing peripherally-acting CB1 receptor blockers for metabolic and fibrotic diseases.

Therapeutic areas: GastroenterologyPulmonologyMetabolic DisordersNephrologyRheumatologyEndocrinologyRare Diseases
Modalities: Small molecules (CB1 inverse agonists/antagonists)
Industry: Biotech

Drug pipeline

1 asset

zevaquenabant

Beyond the preview

Go deeper on Inversago Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inversago Pharma.

Explore the full profile